Pre-Clinical Research

We are constantly searching evidence for new indications of oncolytic virotherapy application and the pre-clinical data is promising.

Arrow Down Icon

Effect of the oncolytic ECHO-7 virus RIGVIR® on the viability of cell lines of human origin in vitro


Published: 2018. Journal of Cancer. 28 February 2018; 9(6): 1033-1049. doi: 10.7150/jca.23242.

Area: IVC, Riga, Latvia; Faculty of Biology, University of Latvia, Riga, Latvia.

Authors: Tilgase, A., Patetko, L., Blāķe, L., Ramata-Stunda, A., Borodušķis, M., and Alberts, P.

Graphical abstract:
Viability of cancer cells of human origin (gastric adenocarcinoma (AGS; CRL-1739), lung carcinoma (A549; CCL-185), Melanoma (FM-9)

Source: A.Tilgase et J.Cancer 2018 Feb (https://www.ncbi.nlm.nih.gov/pubmed/29581783) And L. Patetko et al. (unpublished)

ECHO-7 Oncolytic Effect: Time and Dose Dependent (Control (●); with Echo-7 1% ();with ECHO-7 10%())

Source: A.Tilgase et J.Cancer 2018 Feb (https://www.ncbi.nlm.nih.gov/pubmed/29581783) And L. Patetko et al. (unpublished)

Biomarker development


As a progressive biomanufacturer we are aware of the great genetic diversity of patients and every type of cancer, thus the use of personalized medicine and biomarkers is one of our main developmental objectives. Biomarkers allow a much faster assessment of the course of treatment and increase the effectiveness of treatment by applying medication, regardless of indication, primarily focusing on genetic features of tumor or patient.

With our significant amount of treatment experience, we are actively working on a line of biomarkers, that demonstrate compliance and efficiency with oncolytic virotherapy, including the cases of early-stage treatment.

ECHO-7 action in melanoma cells